Dyck Birte, Unterberg Matthias, Adamzik Michael, Koos Björn
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44801 Bochum, Germany.
Pathogens. 2024 Jan 20;13(1):89. doi: 10.3390/pathogens13010089.
Sepsis, a severe global healthcare challenge, is characterized by significant morbidity and mortality. The 2016 redefinition by the Third International Consensus Definitions Task Force emphasizes its complexity as a "life-threatening organ dysfunction caused by a dysregulated host response to infection". Bacterial pathogens, historically dominant, exhibit geographic variations, influencing healthcare strategies. The intricate dynamics of bacterial immunity involve recognizing pathogen-associated molecular patterns, triggering innate immune responses and inflammatory cascades. Dysregulation leads to immunothrombosis, disseminated intravascular coagulation, and mitochondrial dysfunction, contributing to the septic state. Viral sepsis, historically less prevalent, saw a paradigm shift during the COVID-19 pandemic, underscoring the need to understand the immunological response. Retinoic acid-inducible gene I-like receptors and Toll-like receptors play pivotal roles, and the cytokine storm in COVID-19 differs from bacterial sepsis. Latent viruses like human cytomegalovirus impact sepsis by reactivating during the immunosuppressive phases. Challenges in sepsis management include rapid pathogen identification, antibiotic resistance monitoring, and balancing therapy beyond antibiotics. This review highlights the evolving sepsis landscape, emphasizing the need for pathogen-specific therapeutic developments in a dynamic and heterogeneous clinical setting.
脓毒症是一项严峻的全球医疗挑战,其特征为高发病率和高死亡率。2016年第三届国际共识定义工作组重新定义强调了其复杂性,即“由宿主对感染的失调反应引起的危及生命的器官功能障碍”。历史上占主导地位的细菌病原体存在地域差异,这影响着医疗策略。细菌免疫的复杂动态过程涉及识别病原体相关分子模式、触发先天免疫反应和炎症级联反应。失调会导致免疫血栓形成、弥散性血管内凝血和线粒体功能障碍,从而导致脓毒症状态。历史上病毒性脓毒症不太常见,但在新冠疫情期间出现了范式转变,凸显了理解免疫反应的必要性。维甲酸诱导基因I样受体和Toll样受体起着关键作用,且新冠疫情中的细胞因子风暴与细菌性脓毒症不同。像人巨细胞病毒这样的潜伏病毒通过在免疫抑制阶段重新激活来影响脓毒症。脓毒症管理中的挑战包括快速病原体鉴定、抗生素耐药性监测以及平衡抗生素以外的治疗。本综述强调了脓毒症不断变化的形势,强调在动态且异质性的临床环境中针对病原体进行治疗开发的必要性。